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a  b  s  t  r  a  c  t
We  previously  created  a  live  vaccine  against  equine  inﬂuenza  based  the  new  reassortant  cold-adapted
(Ca)  strain  A/HK/Otar/6:2/2010.  The  live  vaccine  contains  surface  proteins  (HA, NA)  from  the  wild-type
virus  A/equine/Otar/764/2007  (Н3N8; American  Lineage  Florida  Clade  2),  and  internal  proteins  (PB2,  PB1,
PA,  NP,  M,  NS)  from  the  attenuated  Ca donor  virus  A/Hong  Kong/1/68/162/35CA  (H3N2).  To  determine
the  safety  and  duration  of  the  protective  immune  responses,  90 yearlings  were  intranasally  vaccinated
in  single  mode,  double  mode  at an  interval  of  42  days  (107.0 EID50/animal  for both  vaccinations),  or  with
PBS  (control  group).  Ten  animals  from  each  group  were  challenged  with  the  homologous  wild-type  virus
A/equine/Otar/764/07  (Н3N8)  at 1,  2,  3,  4, 5, 6,  9 and  12  months  after  vaccination.  Similarly,  10  animals
from  each  group  were  challenged  with  the  heterologous  wild-type  virus  A/equine/Sydney/2888-8/07
(Н3N8; American  Lineage  Florida  Clade  1) 12 months  after  vaccination.  The vaccine  was  completely
safe,  and  single  intranasal  vaccination  of yearlings  was capable  of inducing  statistically  signiﬁcant  (fromearlings P  =  0.03  to  P < 0.0001)  clinical  and virological  protection  against  the homologous  virus;  however,  only
double  mode  vaccination  generated  signiﬁcant  (from  P =  0.02  to  P < 0.0001)  protection  against  the  het-
erologous  virus  at 12  months  (observation  period).  Interestingly,  this  vaccine  enables  the differentiation
of  infected  and  vaccinated  animals.  On  this  basis  of  this  study,  we  recommend  double  intranasal  admin-
istration  of  this  vaccine  at an  interval  of  42  days  in  veterinary  practice.
©  2014  The  Authors.  Published  by Elsevier  Ltd.  This  is  an open  access  article  under  the  CC  BY-NC-SA. Introduction
Equine inﬂuenza virus (EIV) is the leading viral cause of respi-
atory disease in horses. Though subtype 1 (Н7N7) has not been
eported in recent years, subtype 2 (Н3N8) is currently a signiﬁcant
ealth risk to horses and economic problem in horse breeding [1].
urrent vaccination strategies for EIV generally rely on inactivated
r modiﬁed-live vaccines.
Whole  inactivated vaccines and subunit vaccines were widely
ntroduced in the 1960s. These vaccines offer the advantages of
afety and the absence of viral replication [2]; however, they only
enerate a short immune response, requiring multiple vaccina-
ions. For example, formation of immunity lasting 12 months
sing inactivated vaccines requires triple immunization (two at an
nterval of 4–6 weeks, the third at 5–6 months) [3–5]. Moreover,
∗ Corresponding author at: Zhambulskaya oblast, Kordaiskiy rayon, Gvardeiskiy
80409,  Kazakhstan. Tel.: +7 72636 72228; fax: +7 72636 72228.
E-mail  address: tabynov 81@mail.ru (K. Tabynov).
ttp://dx.doi.org/10.1016/j.vaccine.2014.03.095
264-410X/© 2014 The Authors. Published by Elsevier Ltd. This is an open access article unlicense (http://creativecommons.org/licenses/by-nc-sa/3.0/).
according to Newton et al. [6], horses are most vulnerable to EIV
infection under ﬁeld conditions between the second and third
administration of inactivated vaccines.
Live canarypox vector vaccines are also applied in practice and
like some inactivated vaccines [7,8], can induce both humoral
and cellular immune responses [9,10]. However, three doses of a
canarypox vector vaccine are required to form a protective immune
response lasting 12 months (two at an interval of 35 days, a third
at 6 months) [11]. Moreover, when administered with adjuvants,
both live canarypox vector vaccines and inactivated vaccines may
induce adverse local reactions [11,12].
A live attenuated vaccine based on cold-adapted (Ca) strains has
provided the most encouraging results with regards to the forma-
tion a long-lasting immune response at a minimal multiplicity of
administration. The most signiﬁcant advantage of this vaccine is
its ability to generate a similar immune response to the immune
response observed during natural infection [13,14]. Additionally,
Ca EIV strains are unable to reproduce at the higher temperatures in
the lower respiratory tract, where wild-type viral replication is usu-
ally accompanied by development of bronchitis, pneumonia and
der the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
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ulmonary edema [14]. In addition, vaccines developed from Ca
trains can generate cross-reactivity of the immune system, which
s very important in view of the antigenic variation (antigenic drift)
bserved in EIV [13]. The protective immune response produced in
orses after single intranasal application of the live attenuated Ca
accine lasts at least 6 months [15].
We designed a live vaccine against EIV based on the novel
eassortant Ca strain A/HK/Otar/6:2/2010 containing surface pro-
eins (HA, NA) from the wild-type strain A/equine/Otar/764/2007
Н3N8) and internal proteins (PB2, PB1, PA, NP, M,  NS) from the
ttenuated Ca donor strain A/Hong Kong/1/68/162/35CA (H3N2).
reviously, we showed that intranasal administration of this vac-
ine was completely safe for pregnant mares and foals, and
nduced secretory antibody (IgA) production and a cellular immune
esponse, as well as clinical and virological protection against chal-
enge with a homologous wild-type inﬂuenza virus up to 28 days
fter a single immunization in foals [16,17]. As a logical contin-
ation, we investigated the duration of the protective immune
esponse formed against homologous and heterologous viruses
sing different modes of immunization in horses.
. Materials and methods
.1.  Vaccine strain
The  modiﬁed-live EIV vaccine based on the reassortant Ca strain
/HK/Otar/6:2/2010 was created as described previously [18].
.2.  Vaccine preparation
The  virus was cultured in 10-day-old speciﬁc pathogen
ree (SPF) chicken embryos (CE; LOHMANN TIERZUCHT GmbH,
ermany) at 34 ◦C, after infection of the allantoic cavity at a dose
f 10,000 EID50 (Embryo Infectious Dose)/0.2 ml.  After incubation
or 48 h, the CE were cooled to 2–8 ◦C, allantoic ﬂuid was  collected
nd clariﬁed by centrifugation at 9000 × g for 30 min, mixed in a 1:1
atio with sterile stabilizing medium containing 12% peptone from
asein (Sigma–Aldrich, Germany) and 6% lactose (Sigma–Aldrich),
ixed at 300 rpm for 30 min  at room temperature, aliquoted into
 ml  ampoules, lyophilized and stored at 2–8 ◦C.
.3.  Animals and bioethics
Two  hundred seventy purebred Kazakh dual-purpose
ugalzhar yearlings of both sexes aged 1–1.5 years were used.
ll yearlings were seronegative for EIV. Drinking water and hay
ere available ad libitum and pelleted feed was provided twice
aily; all animals were treated to control their gastrointestinal
arasitic burden. During post-challenge, the animals were housed
n a special isolation ward to prevent the wild-type virus spreading
o the environment.
This  study was carried out in compliance with national and
nternational laws and guidelines on animal handling. The pro-
ocol was approved by the Committee on the Ethics of Animal
xperiments of the Research Institute for Biological Safety Prob-
ems Science Committee of the Ministry of Education and Science
f the Republic of Kazakhstan (Permit Number: 0912/407).
.4.  Vaccine administration
Three  groups containing 90 yearlings each were created: sin-
le vaccination group; double vaccination group at an interval of
2 days; and control group. Intranasal vaccination with the live-
odiﬁed reassortant Ca strain A/HK/Otar/6:2/2010 vaccine at a
ose of 107.0 EID50/animal (1 ml  per nostril) was performed using
 system designed for administration of the Flu AvertTM IN vaccine2 (2014) 2965–2971
(Heska  Corporation, Loveland, CO, USA). Booster vaccination was
performed using the same dose and method. The control groups
were administered phosphate buffered saline (PBS) in the same
manner.
2.5. Assessment of vaccine safety
2.5.1. Clinical monitoring
Monitoring  of the general condition of the yearlings was car-
ried out for 21 days post-vaccination (PV) using the point system
[11], in which the following parameters are scored: general health:
normal general state (score = 0), illness/depression/normal appetite
(1), illness/depression/loss of appetite (2), dehydration (2), exhaus-
tion (4), inability to stand (30), on the edge of death (50), and
death (100); respiratory observations: shortness of breath (2), dys-
pnea (4), cough 2–5 times in 10 min  (1), cough 6–20 times in
10 min  (2), cough more than 20 times in 10 min  (3); ocular observa-
tions: lacrimation (1), moderate mucopurulent secretion (2), severe
mucopurulent secretion (4), mild conjunctivitis (2), strong con-
junctivitis (4); nasal observations: serous secretion of mucus nasal
discharge (1), moderate mucopurulent nasal discharge (2), severe
mucopurulent nasal discharge (4), sneezing 2–5 times in 10 min (1),
sneezing 6–20 times in 10 min  (2), sneezing more than 20 times in
10 min  (3); rectal temperature: 38.5–39.0 ◦C (1), 39.1–39.5 ◦C (2),
and above 39.6 ◦C (3).
2.5.2.  Viral shedding in the upper airway
Nasopharyngeal swabs were collected from all groups on days
1, 3, 5 and 7 PV, placed into tubes containing 1 ml  of viral trans-
port medium (phosphate-buffered saline containing 40% glycerol
and 2% antibiotic solution [1000 U/ml benzylpenicillin, 1000 U/ml
streptomycin, 250 mg/ml  fungizone]) and stored at −70 ◦C until
analysis. The viral titers were determined using 10-day-old CE, cal-
culated using the method of Reed and Muench [26] and expressed
as log10 EID50/0.2 ml.  The speciﬁcity of the virus was  determined
using the commercial Directigen Flu A rapid assay (Becton Dickin-
son, Franklin Lakes, NJ, USA).
2.5.3. Serology after vaccination
Blood  samples were collected from the animals in each group
1, 2, 3, 4, 5, 6, 9 and 12 months PV for the detection of antibod-
ies against EIV using the hemagglutination inhibition (HAI) assay.
Before sampling, the animals were sedated with 20–40 g/kg deto-
midine (Pﬁzer Animal Health, New York, NY, USA). Blood samples
were collected via jugular venipuncture into serum separator tubes
(Vacutainer; Becton Dickinson, USA) for isolation of serum. The
HAI assay was performed according to Ref. [18] using chicken red
blood cell suspensions (1%). The native virus A/HK/Otar/6:2/2010
(working  dose of 4 hemagglutinating units) was used as the antigen.
2.6. Challenge study
Ten  yearlings from single vaccinated group or double vaccinated
group or control group were challenged with the homologous wild-
type virus A/equine/Otar/764/07 (Н3N8) at 1, 2, 3, 4, 5, 6, 9 and 12
months PV. Similarly, 10 yearlings from single vaccinated group or
double vaccinated group or control group were challenged with the
heterologous wild-type virus A/equine/Sydney/2888-8/07 (Н3N8;
American Lineage Florida Clade 1; kindly provided by the Institute
of Microbiology and Virology, Almaty, Kazakhstan) at 12 months
PV. The animals were individually exposed to the challenge viruses
(108 EID50 per animal) by connecting a SaHoMaTM-II mobile ultra-
sonic nebulizer (NEBU-TEC International med. Produkte Eike Kern
GmbH, Germany) to a head hood attached to the horse’s head; the
aerosol was generated from 7.5 ml  egg allantoic ﬂuid.
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Clinical observations and body temperature were monitored
aily for 21 days post-challenge as described above. Serum sam-
les were collected on day 28 PC to determine the accumulation
f inﬂuenza virus antibodies using the HAI assay, using the native
iruses A/equine/Otar/764/07 (Н3N8) and A/equine/Sydney/2888-
/07 (Н3N8) in working doses of 4 hemagglutinating units as
ntigens. Nasal swabs were taken from the animals on days 1, 3,
 and 7 post-challenge to assess the degree of viral shedding as
escribed above.
.7.  Statistical analysis
The  signiﬁcance of the differences between groups were deter-
ined using two-way ANOVA followed by Tukey’s multiple
omparisons test; P < 0.05 was considered signiﬁcant.
. Results
.1. Safety of the vaccine in yearlings after prime and booster
accination
The  vaccine was completely safe for yearlings in both single
nd double intranasal administration mode. After the prime
nd booster vaccinations, the general clinical status and body
emperature of the yearlings remained within the normal limits
hroughout the observation period (21 days), with a rectal temper-
ture of 37.5–38.5 ◦C. Lacrimation, mucopurulent discharge, signs
ig. 1. Duration of the protective immune response in yearlings after prime and boos
nt times after prime or booster vaccination of yearlings, the animals (including the 
/equine/Otar/764/07 (H3N8; 108 EID50/animal). The protection was  evaluated using t
hallenge are presented) as well as the duration of clinical signs and viral shedding (B an
wabs was  0.5 log10 EID50/0.2 ml.  Data are mean ± standard error (SE); NS – non-signiﬁc
accinated vs. single vaccinated groups (from P = 0.01 to P < 0.0001); two-way ANOVA fol2 (2014) 2965–2971 2967
of  conjunctivitis or discharge from the nose was not observed in
any vaccinated animal (data not shown).
Low vaccine viral shedding was  observed in the upper respi-
ratory organs. After the prime vaccination, the virus was  shed in
47.7% (43/90) of animals on day 1 and 26.6% (24/90) on day 3,
with titers ranging from 0.75 to 1.5 log10 EID50/0.2 ml  (1.02 ± 0.04
and 1.29 ± 0.05 log10 EID50/0.2 ml  at 1 and 3 days PV, respectively).
After the booster vaccination, the virus was only shed on day 1
by 31.1% (28/90) of yearlings at titers ranging from 0.75 to 1.25
log10 EID50/0.2 ml  (0.94 ± 0.04 log10 EID50/0.2 ml).
3.2. Duration of the protective immune response in yearlings
after  prime and booster vaccination
As shown in Fig. 1 or Supplementary Table 1, both prime and
booster vaccination of yearlings generated a protective immune
response lasting 12 months (the observation period). After chal-
lenge with the wild-type homologous virus A/equine/Otar/764/07
(H3N8), the severity and duration of the clinical signs of disease,
as well as the intensity and duration of viral shedding in the
upper airway were signiﬁcantly lower (from P = 0.03 to P < 0.0001)
throughout the observation period in the vaccinated animals than
the control group. The severity of the clinical signs of disease, the
intensity of viral shedding, as well as the duration of these parame-
ters post-challenge increased as the length of time between the
prime or booster vaccination. This effect was most pronounced
in the single vaccination group, in which 90% (9/10) of the ani-
mals post-challenged at 4 months PV displayed clinical signs
ter immunization with the modiﬁed live Ca viral vaccine against EIV. At differ-
control group; PBS) were post-challenged with the wild-type homologous virus
he intensity of clinical signs (A) and viral shedding (C, the titers for day 3 post-
d D) post-challenge. The limit of detection of viral shedding from nasopharyngeal
ant; *vaccinated groups vs. control groups (from P = 0.03 to P < 0.0001);  double
lowed by Tukey’s multiple comparisons test.
2968 K. Tabynov et al. / Vaccine 32 (2014) 2965–2971
Fig. 2. Formation of a cross-protective immune response in yearlings after prime and booster immunization with the modiﬁed live Ca viral vaccine against EIV. Twelve
months after prime or booster vaccination of yearlings, the animals (including the control group; PBS) were post-challenged with the wild-type heterologous virus
A/equine/Sydney/2888-8/07 (H3N8; 108 EID50/animal). The protection was evaluated using the intensity of clinical signs (A) and viral shedding (C), and duration of clinical
signs and viral shedding (B and D) post-challenge. The limit of detection of viral shedding from nasopharyngeal swabs was 0.5 log10 EID50/0.2 ml.  Data are mean ± standard
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f disease for 7.3 ± 0.3 days, and viral shedding (mean titer of
.77 ± 0.2 log10 EID50/0.2 ml)  for 3.93 ± 0.5 days. The protective
mmune response was signiﬁcantly greater in the double vacci-
ation group than the single vaccination group during the entire
bservation period (from P = 0.01 to P < 0.0001). For example, when
he double vaccination group were challenged at 4 months after
he booster vaccination, no clinical signs of disease were observed
n any animal (0/10) and viral shedding only occurred in 30% of
he animals (3/10; mean titer of 0.6 ± 0.05 log10 EID50/0.2 ml)  for a
ean duration of 0.9 ± 0.4 days. Moreover, shedding of the wild-
ype virus through the upper airway was not observed in any animal
ost-challenge up to the third month after the booster vaccina-
ion. When challenged 12 months after the booster vaccination,
0% (4/10) of animals displayed clinical signs of inﬂuenza infection,
nd viral shedding was observed in 90% of the animals; however, at
 titer more than 3000 times lower (1.07 ± 0.1 log10 EID50/0.2 ml)
han that of the control group. It should be noted that the highest
iral shedding titers were observed on day 3 post-challenge in all
roups.
After challenge of the control groups, the infection manifested
n the form of depression with reduced appetite (100%), cough
80–100%), lacrimation or mild mucopurulent discharge (10–20%),
arious nasal discharge (50–80%) and an increase in body temper-
ture over 38.5 ◦C (100%). Two different peaks in the clinical signs
f infection and body temperature were observed in the control
roups, on days 2–3 and 10–12 post-challenge. The same pattern of
ymptoms (except for lacrimation) were also observed in the vac-
inated groups post-challenge; however, these parameters were
igniﬁcantly less severe with only a single peak observed at daysinated vs. single vaccinated groups (from P = 0.001 to Р < 0.0001); two-way ANOVA
2–3  post-challenge. An exception to this occurred in the single
vaccination group, in which a second peak of clinical signs was
observed 9–10 days after post-challenge at 6 months PV (data not
shown).
3.3. Evaluation of the cross-protective immune response after
prime  and booster vaccination
Twelve  months after the prime and booster vaccination, the
animals were challenged with the heterologous wild-type virus
A/equine/Sydney/2888-8/07 (H3N8). Single vaccination did not
provide signiﬁcant (P > 0.05) protection in terms of any tested
parameter (clinical signs of disease, viral shedding, or the dura-
tion of these parameters) compared to the control group (Fig. 2
or Supplementary Table 2). In double vaccination mode, the vac-
cine induced a statistically signiﬁcant (from P = 0.02 to P < 0.0001)
protective immune response within the speciﬁed period after
vaccination, not only in comparison with the control group, but
also compared to the single vaccination group. In the control
group, the clinical signs of disease, viral shedding and the dura-
tion of these parameters post-challenge with the heterologous
virus A/equine/Sydney/2888-8/07 (H3N8) were the same, but sig-
niﬁcant (P < 0.0001) less pronounced, as post-challenge with the
homologous virus A/equine/Otar/764/07 (H3N8). For example,
when the animals in the control group were challenged with
A/equine/Sydney/2888-8/07 (H3N8), the total score for the clin-
ical symptoms was  27.4 ± 3.5 with duration and 11.6 ± 0.2 days,
compared to 36.8 ± 0.8 and 16.3 ± 0.2, respectively for the virus
A/equine/Otar/764/07 (H3N8).
K. Tabynov et al. / Vaccine 32 (2014) 2965–2971 2969
Fig. 3. Hemagglutination inhibition titers for the vaccinated animals after challenge with the homologous virus A/equine/Otar/764/07 (H3N8) and heterologous virus
A/equine/Sydney/2888-8/07 (H3N8). Animals were challenged with the homologous virus 1, 2, 3, 4, 5, 6, 9 or 12 months after prime or booster vaccination (A), or the
heterologous virus 12 months after the prime or booster vaccination (B). The animals in the control group (PBS) were challenged at the same age. Data are geometric mean
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s. single vaccinated groups (from P = 0.01 to P = 0.004); two-way ANOVA followed 
. Serology
Neither the prime or booster vaccination did not induced accu-
ulation of detectable antibody titers to the homologous EIV H3N8
n the HAI assay over the entire 12-month observation period
data not shown). In the single vaccinated group, double vaccinated
roup and control group which were post-challenged at different
imes PV (up to 12 months), signiﬁcant antibody titers against H3N8
ere detected in the HAI assay on day 28 post-challenge (Fig. 3 or
upplementary Table 3). The highest antibody titers post-challenge
ere observed in the double vaccinated group, with signiﬁcantly
from P = 0.02 to P = 0.0003) higher antibody titers when post-
hallenged 5 months after the booster vaccination compared to the
ther single vaccinated and control groups.
. Discussion
Here we present new data on the duration of the protective
mmune response formed in yearlings after prime and booster
mmunization with a modiﬁed live viral vaccine against EIV based
n the novel Ca reassortant strain A/HK/Otar/6:2/2010. This vac-
ine was developed in response to a serious epizootic outbreak
f equine inﬂuenza A (H3N8) in Kazakhstan in 2007 [19], when
pproximately 200,000 horses became ill, of which 50,000 horses
 including 40,000 foals – died. Strain A/equine/Otar/764/2007
H3N8)  was isolated from the epizootic outbreak and subse-
uently used to generate the Ca vaccine strain A/HK/Otar/6:2/2010.
hylogenetic analysis of the HA gene of A/equine/Otar/764/2007
H3N8)  demonstrated that this strain belongs to the Ameri-
an Lineage Florida Clade 2 and has 99.99% homology to the
train A/equine/Richmond/1/2007 (H3N8) [18], which was rec-
mmended by the Ofﬁce International des Epizooties for the
roduction of a vaccine against EIV [20].
One objective of this study was to investigate the safety of our
accine in yearlings. Both single and double intranasal administra-
ion of the live vaccine were harmless to yearlings, as no clinical
igns of disease were observed in any animal during the observa-
ion period, and viral shedding only occurred at low titers and in
ess than in 50% of the animals. These results are consistent with
ur earlier studies [16,17], which demonstrated that the reassor-
ant Ca strain A/HK/Otar/6:2/2010 could only replicate in the upper
espiratory organs and did not induce any clinical manifestationuble vaccinated vs. control groups (from P = 0.02 to P = 0.0003); double vaccinated
ey’s multiple comparisons test.
of  EIV (or even of a generalized infectious process) in yearlings or
pregnant mares.
The  most interesting results of this work are the data on
the duration of the protective immune response generated in
yearlings after prime and booster immunization. We  provide
the ﬁrst demonstration that a single intranasal administration of
the Ca live vaccine in yearlings generated signiﬁcant clinical and
virological protection against homologous wild-type virus, with
this protection lasting for 12 months. Previously, it was reported
that single vaccination with a commercial vaccine of a similar type
(Flu Avert TM; Heska Corporation) generated a protective immune
response lasting 6 months [15].
Another interesting ﬁnding was  that double intranasal adminis-
tration of the vaccine to yearlings at an interval of 42 days not only
provided signiﬁcant clinical and virological protection against the
wild-type virus compared to single vaccination, but was also capa-
ble of inducing an immune response which prevents viral shedding
during the 3 months after the booster immunization. Similar results
were previously achieved using an immunization scheme patented
by Intervet International BV (Boxmeer, the Netherlands; US Patent
no. US 7,601,502 B2), in which the horses are ﬁrst vaccinated with
a live Ca vaccine and then receive booster immunizations with an
inactivated EIV vaccine at intervals of at least 8 weeks. Generation
of similar immunity in horses post-challenge was also reported for
a live canarypox vector vaccine containing the adjuvant carbopol
[21]. However, this is the ﬁrst report of the development of a pro-
tective immune response which prevents viral shedding in horses
after double immunization with a live vaccine against EIV. Another
advantage of double vaccination mode (over single vaccination) is
that it induced signiﬁcant clinical and virological protection against
the heterologous wild-type virus A/equine/Sydney/2888-8/07
(H3N8)  for 12 months after the booster immunization. The results
obtained in this study suggest that our vaccine is a good alter-
native to inactivated and recombinant vector vaccines. However,
despite this, there are some concerns about the safety of live attenu-
ated vaccines based on Ca reassortant strains, which are associated
with the risk of reversion of the vaccine virus, or worse, with reas-
sortment of the vaccine virus with a circulating wild-type virus
in live animals followed by emergence of new pathogenic viruses
[2]. In our opinion, these concerns are not unfounded; however,
in practice such problems have not occurred during the 20 years
of positive experience with intranasal live attenuated vaccines
among humans in Western Europe and Russia, and more recently
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n North America (FluMist®) [2]. Previous studies [22] showed that
he vaccine strain A/HK/Otar/6:2/2010 retained the Ca and tem-
erature sensitivity (TS) phenotypes and was genetically stable
uring 20 consecutive passages in CE. According to our unpub-
ished data vaccine strain A/HK/Otar/6:2/2010 is also retained Ca
nd TS phenotypes as well as genetic stability (based on the results
f sequencing the full genome of the virus) over one horse-to-horse
assages.
When used in compliance with current antiepizootic measures,
accine preparations against EIV should not only be safe and
mmunogenic, but may  also provide the ability to differentiate
etween infected and vaccinated animals (DIVA strategy); only live
ecombinant vector vaccines can fully meet the requirements of
his strategy as they express only EIV surface proteins [23]. How-
ver, animals vaccinated with conventional inactivated vaccines
ay also be differentiated from infected animals using serological
ests which detect antibodies against the nonstructural inﬂuenza
iral protein NS1 [24,25]; antibodies against NS1 are only formed
hen live inﬂuenza viruses replicate in vivo. The DIVA strategy is
ot feasible in practice for live attenuated EIV vaccines, since the
accine virus is similar to the wild-type virus and induces an infec-
ious process in vaccinated animals. However, serological studies
ave demonstrated that infected animals can be differentiated from
nimals vaccinated with the modiﬁed live vaccine based on the
a strain A/HK/Otar/6:2/2010. Differentiation was possible as after
he prime vaccination – and most importantly after booster immu-
ization – with the live modiﬁed vaccine, yearlings did not show
etectable antibody titers (>1:10) in the HAI assay for 12 months
V. On day 28 post-challenge with homologous and heterologous
iruses at different times PV (1, 2, 4, 5, 6, 9, 12 months), both sin-
le and double immunized animals accumulated signiﬁcant HAI
ntibody titers (from 168 ± 27 to 672 ± 144). Moreover, it should
e noted that the HAI antibody titers were signiﬁcantly higher in
he vaccinated animals, especially in the double vaccinated group,
han the control group. Antibodies generated as a result of the chal-
enge persisted in the vaccinated and control groups for at least 18
onths (time of observation, data not shown). This data suggests
hat our vaccine will enable the differentiation of infected and vac-
inated animals in practice using widely available serological tests
uch as the HAI.
On  the basis of this data, for practical use we recommend double
ntranasal administration of the modiﬁed live vaccine based on the
a strain A/HK/Otar/6:2/2010 at an interval of 42 days.
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